We describe here a simple and easily manipulatable Escherichia coli-based genetic system that permits us to identify bacterial gene products that modulate the sensitivity of bacteria to tumoricidal agents, such as DMP 840, a bisnaphthalimide drug. To the extent that the action of these agents is conserved, these studies may expand our understanding of how the agents work in mammalian cells. The approach briefly is to use a library of E. coli genes that are overexpressed in a high copy number vector to select bacterial clones that are resistant to the cytotoxic effects of drugs. A tolC bacterial mutant is used to maximize permeability of cells to hydrophobic organic molecules. By using DMP 840 to model the system, we have identified two genes, designated mdaA and mdaB, that impart resistance to DMP 840 when they are expressed at elevated levels. mdaB maps to E. coli map coordinate 66, is located between theparE and parC genes, and encodes a protein of 22 kDa. mdaA maps to E. coli map coordinate 18, is located adjacent to the glutaredoxin (grx) gene, and encodes a protein of 24 kDa. Specific and regulatable overproduction of both of these proteins correlates with DMP 840 resistance. Overproduction of the MdaB protein also imparts resistance to two mammalian topoisomerase inhibitors, Adriamycin and etoposide. In contrast, overproduction of the MdaA protein produces resistance only to Adriamycin. Based on its drug-resistance properties and its location between genes that encode the two subunits of the bacterial topoisomerase IV, we suggest that mdaB acts by modulating topoisomerase IV activity. The location of the mdaA gene adjacent to grx suggests it acts by a drug detoxification mechanism.
The utility of tumoricidal drugs is often limited by a lack of information about the targets of the drug in cells and about the relationship between the presumed drug-target interactions and the cytotoxic effect(s) of the drug. In the absence of such information, it often becomes difficult to modify the drug to maximize desirable interactions and minimize undesirable ones. There are primarily two general approaches for determining how a drug acts in mammalian cells: a biochemical approach and a genetic approach. The biochemical approach is largely based on clever speculation regarding the cellular target(s) of drug action that takes advantage of the structure and properties of the drug or its analogs and often relies on information about variation in cellular responses to the drug as a function of alterations in presumed target levels. The difficulty with this approach is that (i) it is based on a rather "hit-or-miss" process that depends largely on the availability of the above information for any drug and (ii) only limited conclusions can be drawn from the final analysis. Thus, the identification of a protein that is inhibited by a particular drug still fails to address issues such as whether this is the only protein inhibited by the drug; if there are others, which one is inhibited most efficiently by the drug; and, perhaps most important, whether the observed inhibition is responsible for the effects of the drug in cells.
The genetic approach to understanding drug mechanism has the potential to be more informative than the biochemical approach and can certainly deal with issues relating drug targets to drug-induced cellular changes. Thus, the isolation and characterization of mammalian cell lines that are resistant to cytotoxic anticancer agents such as camptothecin, amsacrine, and etoposide (1) (2) (3) reveal that these cells contain reduced levels or resistant forms of topoisomerase I or topoisomerase II enzymes and that the resistance correlates with mutations in genes that encode these enzymes (3) (4) (5) . The difficulty with this approach as a general scheme in mammalian cells stems from the fact that these cells represent a difficult genetic system to work with. Thus, even if a cell line that is resistant to a particular drug has been isolated, in the absence of further information about the gene and mutation involved, one is left with the tedious task of trying to localize the region of the genome responsible (6, 7) .
Thus, we have begun to develop a bacterial system in which we can rapidly analyze drug resistance in a well-developed easily manipulatable genetic system. We have chosen the bisnaphthalimide drug DMP 840 (8) for this initial study because it is a potent antitumor agent, because its presumed cellular target, DNA, is conserved, and because its mechanism of action remains unclear. In vitro, the drug intercalates into DNA with a preference for G+C-rich regions (9) . In cultured mammalian cells, the drug preferentially fractionates and photocrosslinks to DNA (10) and appears to generate nicks but not double-strand breaks or covalent topoisomerase-DNA complexes (9) . Finally, DMP 840-resistance patterns in various mammalian cell lines that are resistant to known topoisomerase I and II inhibitors have not indicated a clear correlation with any of these inhibitors (9) .
We describe here the use of a multicoverage library of Escherichia coli genes to ask whether the overproduction of any one gene product can confer resistance to DMP 840. We have identified two E. coli genes that have this property and by simple genetic manipulation have isolated, mapped, sequenced, and regulated the expression of those genes.* These results confirm the utility of our approach.
MATERIALS AND METHODS
Bacterial Strains, Vectors, and Media. NS3678 is strain AB1157 tolC (ALP1). The tolC mutation is due to a TnlOtetr insertion in that gene that was transduced into NS3678 from strain CS1562 by using phage P1 (11, 12 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. lacIq repressor gene. The tolC-phenotype of NS3678 was initially confirmed and periodically checked by assessing sensitivity of cells to crystal violet (13) . The arabinose promoter vector pBAD-18 is described in ref. 14. M9 medium contains 1 x M9 minimal salts (15) supplemented with 0.3% Casamino acids, 1 mM MgCl2, thiamine (10 jig/ml), and 0.4% glucose.
Induction of the arabinose promotor in pBAD-18 constructs was assessed by adding 0.2% glucose or 0.2% arabinose to the medium. M9 agar is M9 medium with 1.2% (wt/vol) agar. Tumoricidal agent-containing medium was protected from light to avoid photodamage to the drug.
Tumoricidal Agents. DMP 840 was obtained from DuPont Merck. Adriamycin, etoposide, amsacrine, and camptothecin were purchased from Sigma. The 5 mM stock solutions of drugs in dimethyl sulfoxide were stored at -20°C.
Standard Biochemical Procedures. Plasmid DNA isolation, digestion with restriction enzymes (New England Biolabs), and agarose gel analyses were as described (15) . Proteins in crude cell extracts were analyzed by SDS/PAGE. DNA fragments, after being cloned into M13 vectors, were sequenced by the method of Sanger et al. (16) .
Preparation of the pUC19-E. coli Gene Library. High molecular weight genomic DNA isolated from cell line NS3678 was digested with 1 unit of Sau3AI (New England Biolabs) at 37°C for 15 min as described by Pierce et al. (17) . The 2-to 10-kb DNA was isolated from an agarose gel and purified. Fragments were ligated to BamHI-digested pUC19 DNA (New England Biolabs) at a 3-fold molar excess of fragments, and the ligated product was used to transform electrocompetent JM101 bacteria. Colonies were scored after overnight incubation at 37°C on L agar plates containing ampicillin (150 ,ug/ml), isopropyl f3-D-thiogalactoside, and 5-bromo-4-chloro-3-indolyl f3-D-galactoside. Seventy thousand colonies were pooled. This represents the pUC19-E. coli gene library.
Drug-Resistance Assay in NS3678. Exponentially growing cells (OD590 = 0.3) in L broth supplemented with ampicillin (50 ,ug/ml) were diluted in M9 medium and spread onto M9 agar plates containing either glucose or arabinose with or without the tumoricidal agent to be evaluated. Plates were incubated at 37°C and scored after 18, 24, and 48 h for colony number and colony size.
RESULTS
Using a Library of E. coli Genes to Isolate DMP 840-resistant (DMP 840r) Clones of E. coli. The two elements ofthe system: A tolC mutant host and an E. coli gene library. The E.
coli host strain used in these studies (NS3678) contains a TnlO insertion mutation in the tolC gene (tolC-). This gene encodes a component of the E. coli cell membrane and its absence correlates with increased permeability of bacteria to various organic molecules (11) (12) (13) . Consistent with this observation are results indicating that tolC-bacteria can be 50-100 times more sensitive to the cytotoxic effects of DMP 840 than are tolC+ bacteria (N. Henderson, personal communication). Indeed, the elevated DMP 840 sensitivity exhibited by the tolC mutant permits us to carry out experiments at drug concentrations comparable to those used in mammalian cells (9) . A second, less critical, feature of strain NS3678 is the presence of a lacIq gene, which permits us to regulate the lac operon promoter in the vector (pUC19) that was used to construct the E. coli gene library (see below).
To construct a library ofE. coli genes, high molecular weight (>100 kb) E. coli DNA from cell line NS3678 (tolC-) was partially digested with Sau3AI and fragments of 2-10 kb were ligated with BamHI-digested pUC19 vector DNA. The ligated DNA was transformed into JM101 and 7 x 104 transformants were isolated. More than two-thirds of these contain inserts based both on the fraction of white vs. blue colonies on ampicillin/agar plates with isopropyl ,B-D-thiogalactoside and 5-bromo-4-chloro-3-indolyl P-D-galactoside and on an analysis of restriction enzyme digests of plasmid DNAs isolated from >50 transformants. If an average insert size is 4 kb per clone and the E. coli genome is 4 megabases, then 5 x 104 insertcontaining clones would correspond to an =40-fold coverage of the E. coli genome. Plasmid DNA was isolated from the JM101 library and used to construct a similar library in strain NS3678. All subsequent studies were carried out with this NS3678 library. Note, the use of NS3678 genomic DNA to construct the library precludes the isolation of resistant clones containing a functional tolC gene.
Isolation and initial analyses of DMP 84Or clones. To isolate DMP 840r clones, 107_108 cells derived from cultures of NS3678 containing the wild-type pUC19 plasmid or the library of pUC19-E. coli fragments were spread on M9/Casamino acids/minimal agar plates containing 1 ,uM DMP 840 (a concentration 3-fold higher than is needed to prevent colony growth) and the plates were incubated overnight at 37°C. Compared to the number of colonies on plates without the drug, 1 x 10-7 colonies were obtained for the pUC19 culture and 4 x 10-6 colonies were obtained for the culture with the pUC19-E. coli library. To confirm that the DMP 840r phenotype was encoded by a member of the pUC19-E. coli library and was not due to a mutation in the bacterial genome, the plasmid DNA in several of the resistant clones was isolated and used to retransform NS3678. All of the transformants grew normally on minimal/Casamino acids/agar plates with 1 AM DMP 840. To exclude transformants that might act by decreasing permeability of the tolC-cells, we tested each of the DMP 840r transformants for their sensitivity to crystal violet by the standard colony-disk assay (13) , and none demonstrated altered sensitivity.
Localization of Genes Responsible for DMP 8401 to Two Regions of the E. coli Genome. Thirty DMP 840r clones containing members of the pUC19-E. coli library were chosen and plasmid DNAs were isolated from each clone. The insert DNAs from several of these plasmids were labeled with [a-32P]dCTP by random priming, and the probes were hybridized to Biodyne filters (Bellco Glass, Vineland, NJ) (18) containing all 30 DNAs. The results indicated that the isolated clones fell largely into two classes, designated 18 and 66. The probes made from an individual of each class hybridized to all the members of that class but failed to cross-hybridize to any of the members of the other class. Based on differences in the restriction digestion patterns of the 30 plasmid DNAs, there were at least three isolates of each class of inserts in the group of 30. We chose to study further plasmids from each class with the smallest insert sizes: clone 18a contains an insert of 1.6 kb and clone 66a has an insert of 2.1 kb. Both of these clones show a similar pattern of DMP 840r; namely, they are resistant to the drug at 2 ,LM but are sensitive to the drug at 5 ,uM. In contrast, clones containing a random member of the library are sensitive to DMP 840 at concentrations >0.3 ,uM.
Mapping and Sequencing Candidate E. coli Genes Responsible for the DMP 840r Phenotype. The approach used to map and identify genes on the 66a and 18a clones was largely the same for both clones. (i) DNA sequence from both ends of each cloned insert was determined and that sequence was used to search the known E. coli database. (ii) If this failed to locate the insert DNA on the E. coli map, labeled insert DNA probes were used to hybridize to filters containing overlapping members of the Kohara cosmid library of E. coli DNA. (iii) The entire DNA sequence of both inserts was determined and possible open reading frames (ORFs) were noted.
By using 100-150 bp of DNA sequence derived from the ends of the insert in clone 66a, we found no similarity with any E. coli sequence in the GenBank or EMBL data bases by using the BLAST algorithm. In contrast, sequences from both ends of the insert in clone 18a revealed a 98% match to the C-terminal end of the E. coli glutaredoxin gene (grx) on one side and a Genetics: Chatterjee and Sternberg 8952 Genetics: Chatterjee and Sternberg similar match to the sequence of the E. coli rimk other side (data not shown). The E. coli grx-rimk is located at E. coli map coordinate 18 (19) .
To map the insert in clone 66a, we hybridized a from 66a insert DNA against members of the cli library (20) . The probe produced strong positive only two overlapping cosmids, 17B2 and 6B1 shown). The region of overlap shared by these tv located at E. coli map coordinate 66 and is thoug the parE and parC genes, genes that encode the ofE. coli topoisomerase IV (Fig. 1) . The sequence parC are known; both genes are transcribed direction (21) and are separated by an unsequen at least 6 kb. By using primer sets that are intern or parC genes, we could detect no amplificatio DNA insert in a PCR, indicating that the fragm contain either gene (data not shown). Given tha the 66a insert are in an unsequenced region, this this DNA is between parE and parC or between upstream toiC gene (the direction of tolC tra opposite that of parE and parC). The followin, indicate that the former is true. In PCRs contaii E. coli DNA, a primer from one end of the 66a i primer 1) and primers from the C terminus of primer 2) or the N terminus of tolC (Fig. 1, p generated PCR products of 650 bp and 4.5 kb, re second member of the 66 class of inserts (Fig. 1 , c a fragment with one of its ends in the C-termin parE and the other end in unsequenced DNY fragment lacks the N-terminal portion of parn presumably contains a DNA segment that extenc terminus of parE to a point within the unsequ between parE and parC.
The sequences of the entire 66a and 18a determined. Portions of the sequences are shown 2128-bp sequence of 66a contains two nearl' overlapping ORFs (Fig. 2,4 ) that could encode pe 22 kDa. ORF-1 is transcribed in the same directi and parC but appears to lack any obviously translation start signal. In contrast, ORF-2 is tran opposite direction from parE-parC and has an positioned upstream Shine-Dalgarno ribosome The 1569-bp sequence of the 18a insert reveals th in addition to the entire gix gene, an ORF that c a polypeptide of 24 kDa (Fig. 2B) only the construct containing ORF-2 produces a large amount es indicate the of the 22-kDa polypeptide, and only in the presence of the ze to 66a insert inducer arabinose (Fig. 3A, lanes 6-9) (Fig. 3B, lanes 6-9) . 
protein at E. coli map position 66 or the 24-kDa ORF protein at E. coli map coordinate 18 is responsible for the bacteria's resistance to DMP 840. mdaA-and mdaB-Mediated Resistance to Other Topoisomerase-Inhibiting Tumoricidal Agents. Because mdaB is located in a region of the E. coli map that contains the genes for the two subunits of topoisomerase IV, the bacterial homolog of the mammalian topoisomerase II (21), we decided to investigate the effects of overexpressing either the mdaB or mdaA genes on the sensitivity of bacteria to various known inhibitors of the mammalian topoisomerases I and II. The results are summarized in Table 2 and indicate that mdaB confers resistance to Adriamycin and etoposide and mdaA confers resistance only to Adriamycin.
DISCUSSION
Resistance of cells to a variety of tumoricidal agents has been most extensively studied in mammalian cells, where several different mechanisms have been proposed. Resistance has been associated with overexpression of the P180 glycoprotein that mediates the active efflux of toxic hydrophobic molecules from cells (22) . Indeed, a similar membrane pump responsible for the efflux of hydrophobic cations from E. coli has been identified (23) . Another mechanism of drug resistance involves the overproduction of agents that effect the metabolism and inactivation of the drug. Included in this class of resistance are mutants that exhibit elevated levels of redox agents, such as thioredoxin and glutathione (24, 25) . Finally, a class of resistance has been characterized that appears to be associated with drugs that damage DNA. Resistance to agents such as cisplatin and ditercalinium has been attributed to increased cellular DNA repair capacity (25, 26) and resistance to topoisomerase inhibitors is frequently associated with either a reduction in the particular topoisomerase target or specific topoisomerase mutations that interfere with the interaction of the enzyme and the inhibitor (2) (3) (4) (5) .
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How do the mdaA and mdaB genes mediate DMP 840 resistance? The most likely possibilities derive from information about the location of mdaA and mdaB on the E. coli map. Thus mdaB is located between two genes that encode the subunits of the mammalian topoisomerase II analog, E. coli topoisomerase IV. Accordingly, it is tempting to speculate that DMP 840 resistance mediated by the overproduction of the 22-kDa MdaB protein is due to a modulation of topoisomerase IV activity, which is primarily associated with chromosome segregation in E. coli (21) . Consistent with that hypothesis are preliminary results in which tolC-bacteria treated with DMP 840 exhibit a segregation defect. Thus, by 4',6-diamidino-2'-phenylindole dihydrochloride staining of cellular DNA in the presence of the drug, we can see that as much as 50% of the cells contain elongated and deformed nucleoids that have failed to segregate between daughter cells during cell division.
In contrast, DMP 840-treated tolC-cells that overproduce MdaB do not contain this abnormal nucleoid morphology and are indistinguishable from cells not treated with the drug. Additional support for a topoisomerase IV-mediated mechanism of DMP 840 resistance comes from the demonstration that MdaB overproduction also mediates resistance in E. coli to two known topoisomerase II inhibitors, Adriamycin and etoposide. In any case, whatever the effect of mdaB overexpression is on DMP 840 resistance, in the absence of the drug, neither overexpression nor failure to express this gene (e.g., in mdaB gene knockouts) affects cell growth (data not shown).
The mdaA gene is located on the E. coli map adjacent to a gene for glutaredoxin, a prime candidate for a drug detoxification activity. Consequently, it is tempting to speculate that mdaA also encodes such an activity. This conclusion is supported by recent results that indicate that DMP 840-treated cells containing the mdaA plasmid overproduce a drug metabolite barely detectable by HPLC in cells without the plasmid (data not shown). Moreover, mdaA and mdaB probably act by different mechanisms, since both genes afford resistance to Adriamycin, but only the latter provides resistance to etoposide.
A variety of experiments suggest that MdaA and MdaB do not act by increasing either a cellular efflux pump or cellular DNA repair capacity. We have evaluated the efflux pump hypothesis by measuring the uptake of 14C-labeled DMP 840 into cells directly, by taking advantage of the ability of the drug to be photocrosslinked to DNA when exposed to intense light of >360 nm (10) . Our results showed little difference in the level of in vivo crosslinking of the drug to DNA as a function of mdaA or mdaB expression (data not shown). Moreover, these two gene products appear to afford resistance to the lethal effects of various topoisomerase II inhibitors but not the effects of crystal violet, kanamycin, or tetracycline. These results also indicate that neither mdaB nor mdaA overexpression alters the permeability properties of the tolC-host. With regard to the DNA repair hypothesis, we see no effect of mdaA or mdaB arabinose-mediated gene induction on the sensitivity of cells to UV treatment. Moreover, uvrA and recA mutations do not affect the level of resistance to DMP 840 when either of the mda genes is overexpressed.
